Corrigendum to "Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity" [Mol Metab 78 (2023) 101801]
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2024-11-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a2cb6b12f7a44bd6b4923aaac9fbb43b | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Martin Haljeta Friedrichsen |e author |
| 700 | 1 | 0 | |a Lars Endahl |e author |
| 700 | 1 | 0 | |a Frederik Flindt Kreiner |e author |
| 700 | 1 | 0 | |a Ronald Goldwater |e author |
| 700 | 1 | 0 | |a Martin Kankam |e author |
| 700 | 1 | 0 | |a Søren Toubro |e author |
| 700 | 1 | 0 | |a Sune Boris Nygård |e author |
| 245 | 0 | 0 | |a Corrigendum to "Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity" [Mol Metab 78 (2023) 101801] |
| 260 | |b Elsevier, |c 2024-11-01T00:00:00Z. | ||
| 500 | |a 2212-8778 | ||
| 500 | |a 10.1016/j.molmet.2024.102023 | ||
| 546 | |a EN | ||
| 690 | |a Internal medicine | ||
| 690 | |a RC31-1245 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Molecular Metabolism, Vol 89, Iss , Pp 102023- (2024) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S2212877824001546 | |
| 787 | 0 | |n https://doaj.org/toc/2212-8778 | |
| 856 | 4 | 1 | |u https://doaj.org/article/a2cb6b12f7a44bd6b4923aaac9fbb43b |z Connect to this object online. |